NanoViricides' NV-387 Prepared for Ebola Treatment Amidst Outbreak

NanoViricides, Inc., a leader in antiviral drug development, readies its candidate NV-387 for shipment to the Democratic Republic of Congo amid a growing Ebola outbreak. The World Health Organization declared the outbreak a public health emergency on May 16, with over 900 suspected cases and 220 deaths reported across the region.

The NV-387 has demonstrated promising results in animal models, outperforming Remdesivir in a COVID-19 infection model. Unlike existing treatments, NV-387 is available as an oral drug, simplifying its administration under strict isolation protocols needed for diseases like Ebola.

This candidate mimics heparan sulfate proteoglycan, essential for virus cell attachment, providing a broad-spectrum approach effective for various Ebola strains absent a specific treatment.